ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
77.25
+0.79 (+1.04%)
As of 2:41PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close76.46
Open76.88
Bid77.55 x 900
Ask77.57 x 800
Day's Range75.85 - 77.85
52 Week Range62.66 - 94.98
Volume4,790,686
Avg. Volume8,467,646
Market Cap116.227B
Beta (3Y Monthly)0.71
PE Ratio (TTM)28.21
EPS (TTM)2.74
Earnings DateNov 1, 2019
Forward Dividend & Yield4.28 (5.60%)
Ex-Dividend Date2019-10-14
1y Target Est87.80
Trade prices are not sourced from all markets
  • Barrons.com

    CEO Confidence Is Down, Goldman Sachs Says. Look for a Turnaround in 2020.

    CEO confidence has fallen to its lowest level since the global financial crisis more than a decade ago, Goldman Sachs says.

  • What's in Store for Healthcare ETFs in Q3 Earnings?
    Zacks

    What's in Store for Healthcare ETFs in Q3 Earnings?

    With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.

  • AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review
    Zacks

    AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

    AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

  • Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
    Zacks

    Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

    FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

  • PR Newswire

    AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

    - CHMP positive opinion, supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, will now be referred to the European Commission for final approval ...

  • Why Health Care Stocks Can Rebound Despite 2020 Election Turmoil
    Investopedia

    Why Health Care Stocks Can Rebound Despite 2020 Election Turmoil

    Health care stocks, one of the worst performing sectors, could be poised to outperform even as election turmoil heats up next year. Now, better-than-expected earnings from both UnitedHealth Group Inc. (UNH) and Johnson & Johnson (JNJ) have highlighted health care companies' strong earnings amid a dim overall corporate profit outlook. Health care companies have strong underlying businesses, a factor becoming more attractive in the market as investors shift away from “riskier” assets and more expensive, loss-making companies. And from a valuation perspective, the weakness in the health care space has led many investors to buy health care stocks, which are selling at discounted prices.

  • Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
    Zacks

    Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

    Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

  • The Long Decline in AbbVie Is Over
    TheStreet.com

    The Long Decline in AbbVie Is Over

    In his "No-Huddle Offense" segment of Mad Money Wednesday night, Jim Cramer said that as the market is slaughtering the high-growth stocks, those with dividends are coming back into fashion. Cramer said Wall Street is only now waking up to just how transformative Allergan will be to AbbVie, and now's the time to take advantage as the combined company will have both growth and an excellent dividend yield. In this daily bar chart of ABBV, below, we can see that prices have declined the past 12 months but now ABBV is testing the declining 200-day moving average line and the slope of the 50-day moving average line is positive.

  • Top Ranked Income Stocks to Buy for October 17th
    Zacks

    Top Ranked Income Stocks to Buy for October 17th

    Top Ranked Income Stocks to Buy for October 17th

  • T Rowe Price Equity Income Fund's Top 5 Buys in the 3rd Quarter
    GuruFocus.com

    T Rowe Price Equity Income Fund's Top 5 Buys in the 3rd Quarter

    Fund establishes two new holdings and boosts GE stake Continue reading...

  • TheStreet.com

    Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?

    How can the stock of Macy's yield 9% even as the company is profitable and has an improved balance sheet? How is it possible that BP can yield 6% even as the company can increase the dividend and has a much better balance sheet than before? Let's throw in Schlumberger , the pride of the oil patch, a company I have known for almost 40 years when I thought about getting a job there until I realized that I simply wasn't smart enough to get the job.

  • Is AbbVie (ABBV) Stock Undervalued Right Now?
    Zacks

    Is AbbVie (ABBV) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Here is Why Growth Investors Should Buy AbbVie (ABBV) Now
    Zacks

    Here is Why Growth Investors Should Buy AbbVie (ABBV) Now

    AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

  • Reata Successfully Completes Neuromuscular Disorder Study
    Zacks

    Reata Successfully Completes Neuromuscular Disorder Study

    Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

  • Allergan (AGN) Shareholders Approve Acquisition by AbbVie
    Zacks

    Allergan (AGN) Shareholders Approve Acquisition by AbbVie

    Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

  • How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value
    Investor's Business Daily

    How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value

    Reata Pharmaceuticals soared early Tuesday on positive Phase 2 test results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.

  • AbbVie, Bristol-Myers Squibb Getting the Most From Workers
    GuruFocus.com

    AbbVie, Bristol-Myers Squibb Getting the Most From Workers

    Pharmaceutical companies that top the list in terms of sales per employee Continue reading...

  • Zacks

    J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

    J&J (JNJ) comes up with encouraging third-quarter 2019 results.

  • AbbVie (ABBV) Gains As Market Dips: What You Should Know
    Zacks

    AbbVie (ABBV) Gains As Market Dips: What You Should Know

    AbbVie (ABBV) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session.

  • This is Why AbbVie (ABBV) is a Great Dividend Stock
    Zacks

    This is Why AbbVie (ABBV) is a Great Dividend Stock

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

  • Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off
    Investor's Business Daily

    Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off

    Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.

  • Barrons.com

    Gilead Stock Is Up After Releasing Promising Drug Data

    Shares of the biotech firm Gilead Sciences hopped up 0.8% in premarket trading on Friday after the company released data on trials of its experimental drug filgotinib in patients with moderate to severe rheumatoid arthritis.

  • 3 Big Stock Charts for Friday: AbbVie, Chubb and Applied Materials
    InvestorPlace

    3 Big Stock Charts for Friday: AbbVie, Chubb and Applied Materials

    Investors were willing to buy in for a second day in a row, encouraged the economy may get some help after all. Though it peeled back from its intraday high and volume was soft, the S&P 500 still ended Thursday's action up 0.64%.Source: Shutterstock Netflix (NASDAQ:NFLX) led the charge, gaining nearly 5% after Goldman Sachs dished out some kind words about the company. Despite its price-target cut, the investment bank still likes the stock, suggesting it only posed a "modest risk" relative to expectations. Freeport-McMoRan (NYSE:FCX) rallied roughly as much in response to an upgrade from UBS. The bank is a fan of the fact that the mining outfit is selling off some of its weaker assets, and further predicts copper prices will rise from here. * Boston Beer Company Stock Is a Credible Threat to Big Beer Holding the market back was PG&E (NYSE:PCG). The beleaguered utility name, driven to bankruptcy due to its role in California's devastating wildfires, plunged 29% when a judge ruled that key owners of the company's bonds would be allowed to submit a bankruptcy proposal of their own that could work against equity owners.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNone of those names are as compelling as stock charts of AbbVie (NYSE:ABBV), Applied Materials (NASDAQ:AMAT) and Chubb (NYSE:CB) are today. Here's why they earned a spot on watchlists. Applied Materials (AMAT)It has been anything but a straight-line move, but Applied Materials shares have made reliable progress since December's bottom. The ebbs and flows have left behind a well-defined set of rising support and resistance levels, plotted as light blue dashed lines on both stock charts.Assuming the pattern is still repeating itself, there's more upside ahead following August's rebound. Last week and this week gave us more evidence that AbbVie is en route to the upper boundary of its trading range. On the other hand, a couple of new concerns have taken shape. * Click to EnlargeChief among the concerns is the possibility that horizontal resistance has taken shape around $52.40, where the stock topped out in July and then again in September. * The other bearish red flag here is the lack of volume behind the current advance, and the fact that the weekly chart's momentum is waning. That is, the once-rising MACD lines are flattening out. * The good news is, the purple 50-day moving average line served as technical support last week and this week, upping the odds of a breakout beyond the ceiling at $52.40. Chubb (CB)The bears have tried to knock Chubb off of its bullish course several times since December's low. Each time the bulls stepped up to the plate, rekindling the rally. The end result is the establishment of a rising support line marked in yellow on both stock charts.That floor is being tested now thanks to this week's selloff. But, this time is notably different than the prior instances. This time, CB stock is ripe for a lot of profit-taking, and the bulls are on their heels. One more bad day could start a selling avalanche. * Click to EnlargeOn the weekly chart the vulnerability is evident in two ways. One of them is the fact that shares reached a full RSI-overbought condition in August. The other is this week's MACD crossunder. * Those aren't the only red flags on the weekly chart. While it took a day-by-day effort to make it happen, the sheer size and scope of the setback this week translates into the biggest weekly selloff since October of last year. That sweeping change of heart (for no discernible reason) is telling in and of itself. * Underscoring this week's big losses are a couple of days of high volume selling. The would-be sellers have largely tipped their hand. They're worried. AbbVie (ABBV)After an incredible 2017, AbbVie investors have experienced little more than misery. Shares peaked in early 2018, and the downtrend in the meantime was renewed just around each time it looked like it would finally come to a close.The rebound effort that's taken shape since August may end the same way. But, the bottom leading into that rebound was different than any of the previous ones. It may have cut deep enough to act as a capitulation. We need one more good 'umph' to know for sure, as that would finally get a pent-up rebound underway. * Click to EnlargeThe make-or-break line now is the line that connects all the key peaks since May of last year, plotted as a red dashed line on both stock charts. That resistance is being tested right now. * The selling may have hit a climax and set the stage for a prolonged reversal in August, as the weekly chart finally saw its RSI indicator line finally move to the sub-20, oversold level then. * Underscoring the bullish case is the recent action at and around the gray 100-day moving average line. ABBV stock failed to hurdle that line on three attempts earlier this year, but found support there at the beginning of this month (highlighted).As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Super Boring Stocks to Buy With Super Safe Returns * 10 Winning Stocks to Buy and Stick With for the Long Haul * Don't Give Up on These 4 Cannabis Stocks The post 3 Big Stock Charts for Friday: AbbVie, Chubb and Applied Materials appeared first on InvestorPlace.

  • Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs
    Investor's Business Daily

    Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs

    Reata Pharmaceuticals stock jumped Thursday after the biotech company reacquired the rights to several important drugs from pharmaceutical giant AbbVie. Two drugs are in pivotal studies.

  • J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
    Zacks

    J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

    J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.